Abstract
Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tauRD), e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with ΔK280 and two proline point mutations (“anti-aggregation mutant”). The data indicate that the aggregation of tauRD is toxic, and that aggregation and toxicity can be prevented by low molecular weight compounds, notably compounds based on the N-phenylamine core. Thus the cell models are suitable for developing aggregation inhibitor drugs.
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Current Alzheimer Research
Title: N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy
Volume: 4 Issue: 4
Author(s): M. Pickhardt, J. Biernat, I. Khlistunova, Y.-P. Wang, Z. Gazova, E.-M. Mandelkow and E. Mandelkow
Affiliation:
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Abstract: Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tauRD), e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with ΔK280 and two proline point mutations (“anti-aggregation mutant”). The data indicate that the aggregation of tauRD is toxic, and that aggregation and toxicity can be prevented by low molecular weight compounds, notably compounds based on the N-phenylamine core. Thus the cell models are suitable for developing aggregation inhibitor drugs.
Export Options
About this article
Cite this article as:
Pickhardt M., Biernat J., Khlistunova I., Wang Y.-P., Gazova Z., Mandelkow E.-M. and Mandelkow E., N-Phenylamine Derivatives as Aggregation Inhibitors in Cell Models of Tauopathy, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788765
DOI https://dx.doi.org/10.2174/156720507781788765 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)
Protein & Peptide Letters Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Neurotoxic and Neuroactive Compounds from Cnidaria: Five Decades of Research….and More
Central Nervous System Agents in Medicinal Chemistry Potential Photochemical Interactions of UV Filter Molecules with Multichlorinated Structure of Prymnesins in Harmful Algal Bloom Events
Mini-Reviews in Organic Chemistry Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
Current Cancer Drug Targets mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology Impaired Quality Control of Mitochondria Underlying the Pathogenesis of Alzheimer's Disease
Current Drug Targets RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Rationale for the Development of Cholinesterase Inhibitors as Anti- Alzheimer Agents
Current Pharmaceutical Design Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders
Current Molecular Medicine Discovery and Applications of Disulfide-Rich Cyclic Peptides
Current Topics in Medicinal Chemistry Safety of Nanoparticles in Medicine
Current Drug Targets Proteinase K-Resistant Aggregates of Recombinant Prion Protein PrP-(23-98) Are Toxic to Cultured Cells
Protein & Peptide Letters